Long-term survival of participants in the prostate cancer prevention trial.

Publication Type:

Journal Article

Source:

The New England journal of medicine, Volume 369, Issue 7, p.603-10 (2013)

Keywords:

2013, 5-alpha Reductase Inhibitors, Finasteride, Follow-Up Studies, Humans, Incidence, Kaplan-Meier Estimate, Male, Neoplasm Grading, Prostatic Neoplasms, Public Health Sciences Division, RISK, September 2013, Survival Rate

Abstract:

In the Prostate Cancer Prevention Trial (PCPT), finasteride significantly reduced the risk of prostate cancer but was associated with an increased risk of high-grade disease. With up to 18 years of follow-up, we analyzed rates of survival among all study participants and among those with prostate cancer.